Tesamorelin — Bespoke Biology

Growth Hormone Releasing Peptide · Metabolic · Ready to Use

Tesamorelin

A peptide that tells your body to produce more of its own growth hormone — with a particular focus on how your body stores and burns fat. Tesamorelin is especially effective at reducing visceral fat (the deep belly fat that sits around your organs), improving metabolic health, and supporting leaner body composition.

One of the only compounds with clinical trial evidence of selectively targeting specific fat depots — including visceral belly fat and stubborn spot fat accumulations that resist diet and exercise. FDA-approved, Phase III trial-backed, and increasingly used off-label for metabolic body composition goals.

Energy & Metabolic Muscle & Composition Longevity & Cellular Injectable

Learn More

At a Glance

15–18%

Visceral fat reduction documented in Phase III trials over 26–52 weeks

FDA

Approved for visceral fat reduction — one of the only peptides with this designation

Selective

Targets visceral and spot fat depots — subcutaneous fat and BMI unchanged

Your GH

Stimulates your own growth hormone — no synthetic hormones introduced

Visceral · Dorsocervical · Hepatic fat

Clinical evidence for selective reduction across multiple fat depots

Important

Tesamorelin is not FDA-approved for compounded use and is available through licensed compounding pharmacies under medical supervision. This page is for educational purposes only. Always work with a qualified healthcare provider before starting any injectable protocol.

How Tesamorelin Works

Your brain has a gland — the pituitary gland — whose job includes signaling your body to release growth hormone. Growth hormone in turn tells your body how to use energy: burn fat, build muscle, repair tissue, and maintain healthy metabolism. As we age, this signaling naturally weakens and growth hormone levels decline.

Tesamorelin is a synthetic version of the signal your brain already uses to trigger this process — called growth hormone-releasing hormone (GHRH). When you inject it, it amplifies the signal your pituitary gland receives, prompting it to release more of your own natural growth hormone. Your body stays in control of how much it produces — this is not the same as injecting growth hormone directly.

Tesamorelin has a particular affinity for visceral fat — the deep abdominal fat that accumulates around organs and is tightly linked to metabolic disease, insulin resistance, and cardiovascular risk. It's one of the only compounds studied specifically for this type of fat reduction, which is why it was the first GHRH analog to receive FDA approval (for a specific medical indication), and why it remains one of the most clinically credible options in metabolic peptide therapy.

What Tesamorelin Does For Your Body

Tesamorelin's effects extend well beyond visceral fat. Clinical evidence supports selective reduction across multiple fat depots — including stubborn spot fat accumulations that resist conventional approaches — alongside broad metabolic and body composition benefits.

Visceral Belly Fat Reduction

Tesamorelin's most well-documented effect is the selective reduction of visceral fat — the deep abdominal fat that surrounds your organs. Phase III trials documented 15–18% reduction in visceral adipose tissue over 26–52 weeks, with no meaningful change in subcutaneous fat or total body weight. This selectivity is clinically significant: visceral fat is the metabolically dangerous kind, strongly linked to insulin resistance, cardiovascular risk, and systemic inflammation.

Spot Fat Reduction — Dorsocervical

Tesamorelin has demonstrated clinical evidence for reducing dorsocervical fat — the stubborn fat pad at the back of the neck and upper back sometimes called a "buffalo hump." This depot is notoriously resistant to diet, exercise, and most other interventions. Growth hormone-driven lipolysis — the mechanism tesamorelin works through — preferentially targets fat depots with high growth hormone receptor density, which includes both visceral and dorsocervical fat. A 2022 post-hoc analysis of Phase III trial data documented meaningful reductions in dorsocervical fat over 26 weeks alongside the abdominal visceral fat reduction.

Liver Fat Reduction

Tesamorelin reduces hepatic fat fraction — the fat that accumulates inside and around the liver — a finding documented in multiple studies including a 2014 JAMA trial. Liver fat is one of the most metabolically harmful fat accumulations and is closely linked to non-alcoholic fatty liver disease, insulin resistance, and cardiovascular risk. A 2019 study documented approximately 32% reduction in hepatic fat fraction over 12 months in patients with fatty liver disease. As liver fat decreases, metabolic markers including triglycerides and inflammatory signals typically improve alongside it.

Natural Growth Hormone Production

Tesamorelin amplifies the signal your brain already sends to trigger growth hormone release — it does not introduce synthetic growth hormone. The result is a meaningful increase in your body's own natural GH output, the same growth hormone responsible for fat metabolism, muscle maintenance, tissue repair, sleep quality, and metabolic efficiency. Because your body still controls the production process, it remains self-regulating and well tolerated.

Metabolic Health & Blood Sugar

As visceral and hepatic fat decrease, insulin sensitivity typically improves alongside them — creating a positive cascade effect on overall metabolic health. Clinical studies have documented improvements in triglycerides, lipid profiles, and hemoglobin A1c (long-term blood sugar control) in patients using tesamorelin, suggesting a broader metabolic benefit beyond fat redistribution alone.

Lean Muscle & Body Composition

Growth hormone plays a direct role in maintaining lean muscle mass. By increasing GH output, tesamorelin supports the preservation and gradual improvement of lean tissue — particularly relevant as natural GH decline accelerates after 30 and muscle loss becomes harder to prevent. Most clients notice improved body composition — less fat, more definition — that builds progressively across the protocol period.

The Research Behind Tesamorelin

Tesamorelin has one of the strongest clinical evidence bases of any peptide used in compounding — including FDA approval, Phase III trial data, and a growing body of off-label research. Below is what the key studies actually found, in plain language.

FDA Approval · Phase III RCT · LIPO-1 & LIPO-2 Trials

Tesamorelin reduces visceral fat 15–18% over 6–12 months — the data behind FDA approval

Two large randomized, placebo-controlled Phase III trials — LIPO-1 and LIPO-2 — enrolled over 800 patients with HIV-associated lipodystrophy and documented visceral fat accumulation. Across both trials, tesamorelin 2 mg daily reduced visceral adipose tissue by approximately 15% over 26 weeks and 18% over 52 weeks, compared to no meaningful change in the placebo group. Critically, this fat reduction was selective — subcutaneous fat and overall BMI did not change, meaning tesamorelin specifically targeted the deep abdominal visceral fat that carries the highest metabolic risk. These trials formed the basis for FDA approval of tesamorelin (brand name Egrifta) in 2010. The mechanism driving this reduction — growth hormone's effects on fat metabolism — is not specific to HIV and operates the same way in anyone carrying excess visceral fat.

JAMA · 2014 · Stanley et al.

Visceral fat and liver fat both reduced in randomized trial — metabolic benefits confirmed

A randomized clinical trial published in JAMA examined tesamorelin's effect on visceral adipose tissue and liver fat in 50 antiretroviral-treated patients with HIV and abdominal fat accumulation. Tesamorelin produced significant reductions in both visceral fat and hepatic fat — the fat that accumulates inside and around the liver, which is strongly linked to metabolic syndrome and non-alcoholic fatty liver disease. This was one of the first studies to document tesamorelin's dual effect on both visceral and liver fat simultaneously, and it demonstrated measurable improvements in triglycerides alongside the body composition changes. The liver fat reduction finding has since been replicated and extended in later studies.

PMC · 2024 · McLaughlin, Grinspoon, Stanley, Fourman

16% visceral fat reduction confirmed at 12 months in patients on modern antiretroviral therapy

A 2024 study published in PMC leveraged data from a placebo-controlled trial of 61 patients with HIV-associated metabolic liver disease to evaluate tesamorelin's efficacy in patients on modern integrase inhibitor regimens — the most current standard of HIV treatment. After 12 months, the tesamorelin group showed a median 16% reduction in visceral fat cross-sectional area, confirmed by MRI, alongside reductions in hepatic fat fraction and trunk-to-appendicular fat ratio. The study confirmed that tesamorelin's visceral fat-reducing efficacy holds in contemporary treatment contexts, extending the relevance of the original approval data forward to today's patient population.

Off-Label · Non-HIV Populations · Visceral & Spot Fat

The same mechanism works in non-HIV patients — off-label use is growing in clinical practice

Tesamorelin's mechanism — stimulating the pituitary to release growth hormone, which then drives fat metabolism — is not specific to HIV-associated lipodystrophy. Growth hormone promotes lipolysis (the breakdown of stored fat) preferentially in visceral fat depots, where growth hormone receptors are more concentrated than in subcutaneous tissue. This is why tesamorelin produces selective visceral fat reduction without meaningfully changing subcutaneous fat or total body weight. In non-HIV patients with excess visceral fat and metabolic syndrome, smaller studies have shown visceral fat reduction outcomes consistent with the HIV population. Off-label prescribing of tesamorelin for visceral adiposity in non-HIV patients is now increasingly common in clinical practice, under physician judgment, for patients with significant visceral adiposity, appropriate metabolic context, and no contraindications.

Dorsocervical Fat · PMC 2022 · Rahman et al.

Tesamorelin reduces dorsocervical fat — evidence for spot fat reduction beyond the abdomen

A post-hoc analysis of Phase III trial data published in 2022 specifically examined dorsocervical fat — the fat pad at the back of the neck and upper back, sometimes called a "buffalo hump." Among patients who had dorsocervical fat at baseline, 26 weeks of tesamorelin produced meaningful reductions in this specific fat depot alongside the documented visceral fat reduction. This finding is clinically significant because dorsocervical fat is notoriously resistant to diet, exercise, and most pharmaceutical approaches — and represents a specific spot fat accumulation that growth hormone-driven lipolysis can selectively target. This study provides direct evidence that tesamorelin's fat-reducing effects extend to specific problem fat depots beyond the abdominal cavity.

Johns Hopkins · Phase II Trial · NCT03150511

Peripheral nerve injury recovery — tesamorelin's regenerative applications expanding

A Johns Hopkins-sponsored Phase II randomized trial is investigating tesamorelin as a therapy for peripheral nerve injuries — evaluating whether it accelerates axonal regeneration, minimizes muscle atrophy, and improves functional outcomes following surgical nerve repair. The hypothesis is grounded in growth hormone's known role in nerve growth factor production and axonal repair. While this trial is ongoing, it reflects the broader recognition that tesamorelin's growth hormone-stimulating effects extend well beyond fat metabolism — into tissue repair, nerve regeneration, and recovery from physical injury, applications that align closely with the overall Bespoke Biology protocol philosophy.

FDA approval context. Tesamorelin is FDA-approved for visceral fat reduction in HIV-associated lipodystrophy — one of the very few peptides with this level of regulatory endorsement. Off-label use for visceral fat reduction in non-HIV patients is legal under physician judgment and increasingly common in clinical practice. The mechanism driving fat reduction is the same regardless of HIV status. All Bespoke Biology protocols are established during consultation with a provider who will assess whether tesamorelin is appropriate for your specific clinical picture.

Common Questions

Does this come pre-mixed or do I need to prepare it?+

Your Bespoke Biology Tesamorelin comes as a fully pre-blended liquid — ready to draw and inject. There is no mixing or preparation required. Just draw 0.1 mL (10 units) with a fresh syringe and inject. Keep the vial refrigerated and use within 28–30 days of opening.

Why inject into the abdomen specifically — can I use other sites?+

Tesamorelin's primary mechanism targets visceral fat — the deep fat stored in the abdominal cavity. Injecting bilaterally into the abdomen (alternating left and right sides) puts the peptide close to its target tissue and is consistent with how it has been studied clinically. Unlike most other peptides where you can rotate between the abdomen, thigh, and upper arm, Tesamorelin should stay in the abdominal area. Always alternate left and right sides to prevent irritation and ensure consistent absorption.

Is this the same as taking synthetic growth hormone (HGH)?+

No — and this is an important difference. Synthetic HGH is the growth hormone itself, injected directly into your body. Tesamorelin is a growth hormone-releasing hormone (GHRH) analog — it sends a signal to your own pituitary gland to produce more of its own growth hormone. Your body controls how much it releases and regulates the process naturally. This self-regulating mechanism is why Tesamorelin is generally better tolerated than direct GH therapy, with fewer side effects and a lower risk of over-suppression.

How soon will I see results?+

Energy and metabolic changes are often noticed within the first 2–3 weeks. Measurable reductions in abdominal circumference and visceral fat typically become apparent from weeks 4–6. The full body composition benefits are best assessed at the end of a complete 8-week cycle. Clinical studies showed meaningful reductions in visceral fat at 26 and 52 weeks of use, so while 4–8 weeks produces real results, longer-term consistent use compounds the benefit significantly.

Why only twice per week — wouldn't daily injections work better?+

Tesamorelin works by amplifying a pulsatile signal — the natural rhythm your brain uses to tell your pituitary gland to release growth hormone. Daily or more frequent dosing can blunt the receptor's sensitivity over time, reducing effectiveness. Twice-weekly dosing maintains strong receptor response while still providing meaningful GH stimulation across the week. Consistent spacing (e.g. Monday and Thursday) is more important than the specific days — what matters is that the two doses are roughly equidistant in time.

Can I use Tesamorelin alongside other products?+

Yes — Tesamorelin pairs well with other metabolic and longevity protocols. MOTS-c is a particularly complementary pairing, since both work at the metabolic level from different angles (MOTS-c via mitochondrial efficiency, Tesamorelin via GH-driven fat metabolism). NAD+ & Glutathione pairs well for cellular energy support. Let your provider know everything you're taking so they can confirm the combination is appropriate for your goals.

What side effects should I watch for?+

Tesamorelin is generally very well tolerated. The most commonly reported effects are mild and short-lived: redness or irritation at the injection site (alternating sides prevents this from accumulating), mild headache in the first few days, and rare swelling or tingling in the hands and feet — a known GH-related effect that typically resolves quickly. Mild nausea is uncommon. Contact your provider if any side effect feels significant or persists beyond a few days.

How should I store Tesamorelin?+

Keep your vial refrigerated at 35–46°F (2–8°C) at all times. Do not freeze it. Protect it from direct light and heat. Do not shake the vial vigorously. Write the date you first opened it on the label and use within 28–30 days. If you notice cloudiness or discoloration, do not use it — contact your provider for a replacement.

Side Effects to Watch For

Tesamorelin is generally well tolerated. Reported side effects are mild and transient:

/Redness or irritation at the injection site — alternating left and right sides prevents buildup
/Mild headache when first starting — typically resolves within the first few days
/Swelling or tingling in hands and feet (rare) — a known GH-related effect, usually short-lived
/Mild nausea (rare) — typically resolves quickly without intervention

These effects are short-lived and resolve without intervention. Contact your provider if anything feels significant or persists beyond a few days.

Ready to begin

Learn More About Tesamorelin

USA-formulated, lab-verified liquid formula. Ready to use — no mixing required. Protocol guidance provided during your complimentary consultation.

Learn More

515 E Las Olas Boulevard

Suite 1301-L32

Fort Lauderdale, FL 33301

728-300-6020

[email protected]

For educational purposes only. Many compounds referenced on this site are investigational and not FDA-approved.
Always consult a qualified healthcare provider before starting any peptide regimen.